Title of study

    ONTology-based Web Database for Understanding Amyotrophic Lateral Sclerosis (Portugal)

    Acronym for cohort


    Name of Principal Investigator - Title


    Name of Principal Investigator - First name


    Name of Principal Investigator - Last name

    de Carvalho

    Address of institution -Institution

    Instituto de Medicina Molecular

    Address of institution - Street address

    Avenida Professor Egas Moniz

    Address of institution - City


    Address of institution - Postcode




    Contact email
    Funding source

    FCT / Joint Programme - Neurodegenerative Disease Research (FPJ000876-JPND-PS/001/2013)

    Q1a. Please indicate below if your cohort includes or expects to include, incidence of the following conditions?

    Motor neurone diseases

    Q2a. In a single sentence what is the stated aim of the study? (Maximum 30 words)

    To define specific factors that can possibly influence the onset and course of the disease taking into account the genotype-phenotype background.

    Q2b. What distinguishes this case-control study from other studies?

    Multi-center study that translates risk and prognostic factors from specific genotype-phenotype profiles into a disease-specific domain ontology applying sophisticated relevant bio-informatic methods for analysis

    Q3a. i) Number of publications that involve use of your cohort to date


    Q3a. ii) Please give up to three examples of studies to date (PI, Institution, Title of Study)

    Q3b. If data on research outputs are already available please paste the publication list/other data or provide a link to where these data are publicly available

    DOI: 10.1016/j.clinph.2016.02.011, DOI: 10.1007/s12576-016-0484-x, DOI: 10.1016/j.neucli.2016.08.001

    Q3c. If no research has been done as yet, please explain in a few sentences what information (i.e. research findings) you expect will be gained from the case-control study

    Q4a. Study criteria: what is the age range of participants at recruitment? Age in years From:


    Q4a. Study criteria: what is the age range of participants at recruitment? To:

    until death

    Q4b. Study criteria: what are the inclusion criteria?

    Having Motor Neuron Disease, Revised El escorial criteria

    Q4c. Study criteria: what are the exclusion criteria?

    Having other neurological conditions

    Q5a. What is the size of the cohort (i.e. how many participants have enrolled)?


    Q5b. What is the expected number of control participants?


    Q6a. Please describe what measures are used to characterise participants

    Age, gender and ethnic background. Risk factors (trauma, surgery, exercise, smoking habits, lipids blood levels, stress level, place of birth and living, nutritional habits) medication taken, auto-immune diseases, diabetes and other medical disorders, cardiovascular events and other cardiovascular risk factors. Familial history (ALS, other neurodegenerative disorders, dementia, exercise, weight, cardiovascular events).

    Q6b. Are there additional measures for participants with the clinical disorder?

    Yes. Age at disease-onset, Affected region at presentation, Symptoms at onset, Clinical signs, Functional measurement, Progression rate, Laboratory findings (thyroid function, CK, cholesterol, triglycerides, serum albumin, respiratory function tests including spirometry and maximal pressures). Survival (death or ? 23 hours ventilatory support).

    Q6c. Are there defined primary and secondary endpoints (e.g. defined health parameters)?


    If YES please specify

    Q7. What is the study design?

    Prospective cohort|Age|Sex

    Q8. Are your cases matched by

    Q9a. Does your study includes a specialised subset of control participants?


    Q9b. If your study includes a specialised subset of control participants please describe

    Q10a. Is data collection for this study

    Data collection ongoing|Data analysis ongoing

    Q10b. If data collection is ongoing, are there plans to continue the cohort study beyond the current projected end date?

    Yes - intend to apply for funding

    Q11. Are data collected

    Only through the study

    Q12. Is there a system in place to enable re-contact with patients for future studies?


    Q13a. Please give information on data stored in a database (1)


    % Available

    Q13a. Please give information on data stored in a database (2)


    % Available

    Q13a. Please give information on data stored in a database (3)

    Database on spreadsheet (e.g. excel)

    % Available


    Q13a. Please give information on data stored in a database (4)

    Database on paper

    % Available


    Q13a. Please give information on data stored in a database (5)


    % Available

    Please specify language used

    % Available


    Q13b. Please give information on how data is held as individual records


    % Available

    Q14a. Are data available to other groups?


    Q14b. If data is available to other groups what is the access policy/mechanisms for access?

    Q15. What data sharing policy is specified as a condition of use?

    No policy exists

    Q16a. Are tissues/samples/DNA available to other groups?


    Q16b i) If yes, please describe below

    Q16b. ii) In what form are tissues/samples/DNA supplied?

    Q16b iii) Is the access policy/mechanism for obtaining samples the same as that for obtaining data (Q14 above)?

    Q17. Is information on biological characteristics available to other groups?


Types: Case Control Studies, JPND Projects
Member States: JPND, Portugal
Diseases: Motor neurone diseases
Years: 2016
Database Categories: N/A
Database Tags: N/A

Export as PDF